Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries Limited : Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2017 | 08:21pm CET

IRVINE, CA / ACCESSWIRE / October 4, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE: TEVA). Investors, who purchased or otherwise acquired shares from November 15, 2016 through August 2, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the October 23, 2017 lead plaintiff motion deadline.

If you purchased Teva shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Teva issued materially false and/or misleading statements, and/or failed to disclose, that the poor performance of its U.S. generics business resulted in the Company recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva's dividend by 75%. When this information was released, shares of Teva fell in value materially, which caused investors harm according to the lawsuit.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.


Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]

SOURCE: Khang & Khang LLP

© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
03:01p TEVA PHARMACEUTICAL INDUSTRIES : Announces Exclusive Launch of Generic Viread® i..
12:35p BIOTECH MOVERS : Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) And Ampio Pharm..
09:16a TEVA PHARMACEUTICAL INDUSTRIES : Israel-based Teva Pharmaceutical to lay off 14,..
08:48aDJTEVA PHARMACEUTICAL INDUSTRIES : Generics Giant Cuts Staff by 25% -- WSJ
12/14 TEVA PHARMACEUTICAL INDUSTRIES : Globes, Tel Aviv, Israel, Shiri Habib-Valdhorn ..
12/14 TEVA PHARMACEUTICAL INDUSTRIES : Histadrut calls general strike Sunday over Teva..
12/14 TEVA PHARMACEUTICAL INDUSTRIES : CEO tells Netanyahu of hostile takeover risk
12/14 TEVA PHARMACEUTICAL INDUSTRIES : to lay off 14,000 globally; effect on Gurnee fa..
12/14 TEVA PHARMACEUTICAL INDUSTRIES : Gains on Workforce Reductions
12/14 TEVA PHARMACEUTICAL INDUSTRIES : Riots outside Teva's Jerusalem factory over mas..
More news
News from SeekingAlpha
09:49a Teva launches generic Viread in U.S.
08:38a Premarket analyst action - healthcare
07:04a WALL STREET BREAKFAST : Focus Returns To Tax Reform
03:35a YOUR DAILY PHARMA SCOOP : Conatus Looks Undervalued, Teva Announces Restructurin..
12/14 Analysts weigh in on Teva's restructuring plan
Financials ($)
Sales 2017 22 633 M
EBIT 2017 6 276 M
Net income 2017 -
Debt 2017 34 419 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,33x
EV / Sales 2018 2,23x
Capitalization 18 265 M
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 1
Average target price 24,5 $
Spread / Average Target 36%
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON24.03%380 546
NOVARTIS13.16%222 673
PFIZER10.04%217 327
ROCHE HOLDING LTD.3.40%211 657
MERCK AND COMPANY-6.96%152 759